Moreover, there were significant differences between mutations in the original tumor and the site of metastasis, suggesting the need for additional biopsies as a patient's cancer progresses.
So what we're saying is we should have the clinical freedoms to work with the patients for the patients' benefit to work out who takes priority in a cash limited system and make sure the patient gets the quality service that they need for their complaint - not the one that's politically expedient.